Results 61 to 70 of about 246,153 (308)

Membrane Vesicles from Lacticaseibacillus Casei BL23 Exhibit Antimicrobial Activity Against Escherichia coli and Immunostimulatory Effects on Human Peripheral Blood Mononuclear Cells

Advanced Healthcare Materials, EarlyView.
Membrane vesicles derived from the probiotic Lacticaseibacillus casei BL23 demonstrate antimicrobial properties against Escherichia coli and a potential biological effect in improving the overall survival of C. elegans infected with Pseudomonas aeruginosa. These vesicles stimulated immune responses in primary cells without causing toxicity. Our results
Cecilia L. D'Antoni, Leila Pourtalebi Jahromi, Lorenzo Sana, Ana Paula Domínguez Rubio, Maja Dorfner, Jennifer Munkert, Heike Danzer, Philipp Arnold, Mikhail Lebedev, Esther Zanin, Oscar E. Pérez, Gregor Fuhrmann   +11 more
wiley   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

CD207‐Positive Dendritic Cells Promote Emphysema Through CD8+ T Cell Pathway in Chronic Obstructive Pulmonary Disease

Advanced Science, EarlyView.
CD207+ dendritic cells (DCs) drive emphysema by promoting CD8⁺ T cell cytotoxicity via Birbeck granule‐dependent MHC‐I antigen presentation. This DC subset is expanded by cigarette smoke‐induced oxidative stress, which triggers granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) release from airway epithelium.
Shurui Xuan, Yunhui Wu, Feng Liu, Heng Fu, Yaqi Meng, Yingwei Ou, Xijing Yuan, Ian M. Adcock, Man Jia, Xiaoning Zeng, Xin Yao   +10 more
wiley   +1 more source

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. [PDF]

, 2017
Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV).
Ashokkumar, Manickam, Babu, Hemalatha, Buddolla, Viswanath, Chandrasekaran, Padmapriyadarsini, Cheedarla, Narayanaiah, Hanna, Luke Elizabeth, Kailasam, Nandagopal, Precilla, K Lucia, Ramanathan, VD, Sundaramurthi, Jagadish Chandrabose, Swaminathan, Soumya, Vaniambadi, S Kalyanaraman, Vijayan, KK Vidya   +12 more
core   +3 more sources

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

Advanced Science, EarlyView.
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao, Xu‐Ying Pei, Yuan‐Yuan Zhang, Juan Xie, Jing‐Wei Tu, Zhuo‐Jun Liu, Yi‐Yang Ding, Chen‐Hua Yan, Yu‐Hong Chen, Yu Wang, Lan‐Ping Xu, Xiao‐Hui Zhang, Xiao‐Jun Huang, Xiang‐Yu Zhao   +13 more
wiley   +1 more source

Evaluating the neutralizing antibody response to HIV-1 membrane proximal external regional; Implications for vaccine design [PDF]

, 2014
Includes bibliographical references.Inducing broadly neutralizing antibodies targeting the HIV-1 envelope is thought to be crucial for developing an effective vaccine.
Jacob, Rajesh Abraham
core  

A Quantum Framework for Protein Binding‐Site Structure Prediction on Utility‐Level Quantum Processors

Advanced Science, EarlyView.
This study presents a hybrid quantum‐classical framework for accurate prediction of protein structures on utility‐level quantum processors. We evaluate the practical application of the Variational Quantum Eigen‐solver (VQE) in protein structure prediction and demonstrate its superiority over state‐of‐the‐art deep learning methods in molecular docking ...
Yuqi Zhang, Yuxin Yang, William Martin, Kingsten Lin, Zixu Wang, Cheng‐Chang Lu, Weiwen Jiang, Ruth Nussinov, Joseph Loscalzo, Qiang Guan, Feixiong Cheng   +10 more
wiley   +1 more source

Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection [PDF]

, 2005
Worldwide HIV-1 vaccine efforts are guided by the principle that HIV-specific T cell responses may provide protection from infection or delay overt disease. However, no clear correlates of T cell-mediated immune protection have been identified.
Ambrozak, D. R., Bansal, A., Belshe, R., Betts, M. R., Camacho, Z. T., Douek, D. C., Exley, B., Ferrari, G., Gao, F., Goepfert, P., Kilby, J. M., Koup, R. A., Price, David, Roederer, M., Tartaglia, J., Teaberry, V., Tomaras, G., Weinhold, K. J., West, S. M.   +18 more
core   +4 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

HIV prevention clinical trials’ community engagement guidelines: inequality, and ethical conflicts

Global Bioethics, 2020
In 2004 and 2005, the first clinical trials were launched to investigate the use of tenofovir for HIV prevention in Cambodia, Cameroon, Nigeria and Thailand. Controversies erupted over the ethical integrity of the research protocol.
Morenike O. Folayan, Kristin Peterson
doaj   +1 more source